Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0K4GK
|
||||
| Former ID |
DIB018533
|
||||
| Drug Name |
22R-hydroxycholesterol
|
||||
| Synonyms |
22beta-hydroxycholesterol; 22R-OHC
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C27H46O2
|
||||
| InChI |
InChI=1S/C27H46O2/c1-17(2)6-11-25(29)18(3)22-9-10-23-21-8-7-19-16-20(28)12-14-26(19,4)24(21)13-15-27(22,23)5/h7,17-18,20-25,28-29H,6,8-16H2,1-5H3/t18-,20-,21-,22+,23-,24-,25+,26-,27+/m0/s1
|
||||
| InChIKey |
RZPAXNJLEKLXNO-GFKLAVDKSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
7855, 7983970, 10256555, 17501138, 24895852, 46241149, 49688252, 57351298, 75005942, 103114776, 103162244, 103428723, 113461277, 123080470, 126524977, 127346295, 135123118, 135651388, 135764294, 137109197, 139022589, 140154466, 160645367, 162226561, 162817550, 172829375, 179293231, 184582401, 226478367, 242081676
|
||||
| Target and Pathway | |||||
| Target(s) | Oxysterols receptor LXR-beta | Target Info | Agonist | [2] | |
| Oxysterols receptor LXR-alpha | Target Info | Agonist | [2] | ||
| Bile acid receptor | Target Info | Agonist | [3] | ||
| KEGG Pathway | PPAR signaling pathway | ||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Hepatitis Chsa04976:Bile secretion | |||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptorrxr_vdr_pathway:RXR and RAR heterodimerization with other nuclear receptorrxr_vdr_pathway:RXR and RAR heterodimerization with other nuclear receptor | ||||
| Reactome | Nuclear Receptor transcription pathwayR-HSA-159418:Recycling of bile acids and salts | ||||
| PPARA activates gene expression | |||||
| Endogenous sterols | |||||
| WikiPathways | SREBP signalling | ||||
| Nuclear ReceptorsWP299:Nuclear Receptors in Lipid Metabolism and Toxicity | |||||
| Nuclear Receptors Meta-Pathway | |||||
| PPAR Alpha Pathway | |||||
| Liver X Receptor Pathway | |||||
| Adipogenesis | |||||
| SREBF and miR33 in cholesterol and lipid homeostasis | |||||
| Farnesoid X Receptor Pathway | |||||
| Drug Induction of Bile Acid Pathway | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2742). | ||||
| REF 2 | An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996 Oct 24;383(6602):728-31. | ||||
| REF 3 | Oxysterol 22(R)-hydroxycholesterol induces the expression of the bile salt export pump through nuclear receptor farsenoid X receptor but not liver X receptor. J Pharmacol Exp Ther. 2006 Apr;317(1):317-25. Epub 2005 Dec 21. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.